1Matsuzaki I, Suzuki H, Kitamura M, et al. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells[ J]. Oncology,2000,59(4) :336 -343.
2Shimizu T,Shimada H, Ochiai T, et al. Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl transferase and herpes simplex virus thymidne knase) [J]. Cancer Gene Ther, 2001,8(7) :512 -521.
3Matsubara H, Maeda T, Gunji Y, et al. Combinatory anti-tumor effects of electroporatan-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells [ J ]. Int J Oncol,2001,18(4) :825 -829.
4Kim JP,Yu HJ,Lee JH,et al. Results of immunochemo-surgery for gastric carcinoma[J]. Hepatogastroenterology,2001,48(41 ) ;1227- 1230.
5Gochi A, Orita K, Fuchimoto S, et al. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients[J]. Br J Cancer,2001,84(4) :443 -451.
6Iguchi C, Nio Y, Takeda H, et al. Plant polysaccharide PSK:cytostatic effects on growth and invasion : modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface[J]. Anticancer Res,2001,21 (2A) : 1007- 1013.
7Vollmers HP,Hensel F,Hermann R,et al. Tumor-specific apoptosis induced by the human monoclonal antibody SC-1 : a new therapeutical approach for stomach cancer[J]. Oncol Rep,1998,5( 1 ) :35 -40.
8Kamiya K, Konno H,Tanaka T,et al. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody [ J ]. Jpn J Cancer Res, 1999,90(7) :794 -800.
9Kotolff KL, Sztein MB, Wasserman SS, et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection[J]. Infect Immun,2001,69(6) :3581 -3590.
10Gonzalez G, Grombet t, Catala M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein:report of a pilot clinical trial [ J ]. Ann Oncol,1998,9(4) :431 -435.
2Reubi JC, Schaer JC, Markwalder R, et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med. 1997,70:471.
3Fisher WE, Doran TA, Muscarella P, et al. Expression of somatostatin receptor subtype 1 - 5 genes in human pancreatic cancer. J Nat Cancer Inst. 1998,90:322.
4Tang C, Biemond I, Verspaget HW, et al. Expression of somatostatin receptors in human pancreatic tumor. Pancreas. 1998,17:80.
5Scherubl H, Bader M, Fett U, et al. Somatostatin receptor imaging of meuroendocrine gastroenteropancreatic tumors. Gastrnenterol. 1993,105(6) :1705.
6Maria C, Zatelli, Federico tagliati, et al. Somatostatin receptor subtypes 2 and 5 differentially effect proliferation in vitro of the human medullary thyroid carcinoma cell line Tr. The Journal of Clinical endocrinology & metabolism. 2001, 86(5) :216
7Lamberts SW, Reubi JC, Krenning EP. The role of somatostatin analogs in the control of tumor growth. Semin Oncol. 1994,21 (5 Supple 13): 61.
